*Please note the Pre-Conference Focus Day has been Cancelled*

7:30 am Registration Opens

8:50 Chairs Opening Remarks

  • Jonathan Lovell Associate Professor, Biomedical Engineering, University at Buffalo

Clinical Development of Cancer Vaccines: The Landscape & Novel Candidates

9:00 am Cancer Vaccines: The Landscape and the Future


  • Understanding the current preclinical and clinical view of the cancer vaccine
  • Key trends emerging in the space including combinations with other vaccine
    modalities, disease indication, and novel approaches/technologies, and so on
  • A glimpse into the future for cancer vaccines in 2022 and beyond

9:30 am mRNA Approaches for Personalized Cancer Vaccine Development


  • Optimization of an mRNA-based platform for cancer vaccine development
  • Overview of Moderna’s cancer vaccine pipeline and clinical updates

10:00 am A Novel Heterologous Prime Boost Vaccine System To Drive Tumor Specific T Cell Responses For Cancer Immunotherapy


  • Development of a potent heterologous prime/boost immunization approach
    to deliver predicted TSNAs to patients, which is comprised of a replication
    incompetent chimpanzee adenoviral vector (ChAdV) for the prime vaccination
    and a self-replicating, synthetic viral vector (srRNA) for repeated boost
  • Induction of high titer, polyfunctional and durable T-cell responses against nonself
  • Clinical trial updates will be highlighted

10:30 am The DPX Delivery Platform Enables Cancer Vaccines to be Clinically Viable


  • DPX is a unique lipid-in-oil, non-emulsion delivery formulation that educates a targeted and long-lasting immune response in regional lymph nodes
  • DPX can be formulated to deliver a variety of cargo (e.g. peptides, proteins, VLPs, TLRs, mRNA)
  • Proof of concept is clinically demonstrated in several hematologic and solid cancer indications

10:50 am Accelerating the Development of Genomic Vaccines – Insights into Lipid Nanoparticle Design and Scalable Microfluidic Manufacturing

  • Jason Coleman Clinical Application Scientist Lead, Precision nanosystems


  • Acknowledging the complexities and challenges for developing genomic cancer vaccines and how it is critical to have a scalable and robust manufacturing platform for the development of non-viral delivery methods.
  • Sharing insights into a scalable manufacturing platform for RNA-LNPs and the use of this technology for the development of a high-potency self-amplifying (saRNA) LNP vaccine.
  • Highlighting some of the key considerations for the development of a LNP vaccine drug product.

11:20 am Morning Refreshments & Speed Networking

Clinical Development of Cancer Vaccines Continued

12:00 pm Insights to Assist Finding the Right Vaccine Platforms


  • Developing individualised therapeutic cancer vaccines against neoantigens
    arising from somatic gene mutations in malignant cells
  • Demonstrating induction of strong cancer-specific immune responses which lead
    to clinical responses in several patients

12:30 pm Breakthrough 2nd generation technology for LNP manufacture


  • Engineering successful scaleup (not scale out)
  • Pinpointing strategies to address variability
  • Accelerating rapid formulation development

12:45 pm Lunch and Networking

Overcoming the Clinical Translation of Cancer Vaccine Candidates: Next Generation Platforms

1:45 pm The Case for Creating a Broadly Protective Preventative Cancer Vaccine: Report on a Large Canine Clinical Trial Testing the Concept


  • Clinical trials are in progress to demonstrate the feasibility of providing
    prophylactic vaccines that prevent cancer.
  • Partnerships are formed to collaboratively established the viability of early
    cancer diagnosis.
  • FAST vaccine trials are being initiated that could dramatically reduce the time
    and expense of cancer treatments

2:15 pm Synthetic, enzymatically produced DNA for use in DNA vaccines


  • Exploring how 4bbDNA™ confers several benefits over plasmid DNA for use in DNA vaccines, including: Lack of bacterial backbone confers safety benefits and enables dose reduction as compared to plasmid DNA, possibility of tuning immunostimulatory properties of DNA constructs, and greatly reduced timelines of GMP-grade material
  • Collaborating with Takis Biotech and Neomatrix on neoantigen DNA cancer vaccines using osDNA™ constructs showed meaningful immune responses and reduced tumour growth as compared to pDNA in clinically relevant models
  • 4basebio and Neomatrix plan to execute a Phase I clinical trial in 2023 for personalised neoantigen cancer vaccines

2:30 pm Afternoon break and Networking

3:00 pm Short, MHC-I Restricted Epitopes as Potent Cancer Vaccine Antigens when Admixed with a Particle-Inducing Adjuvant System

  • Jonathan Lovell Associate Professor, Biomedical Engineering, University at Buffalo


  • Short MHC-I restricted peptides (9-mers) can induce strong, durable and
    functional antigen-specific CD8+ T cells when displayed on immunogenic
  • Short peptides particles can be used for immunization with higher-order
    multiplexing (ie 60 peptides) and for functional neoantigen discovery
  • Peptide sequences can be systematically interogated to find enhanced
    mimotopes for Class-I tumor-associated self-antigens

3:30 pm Optimizing the Efficacy of mRNA-based Cancer Vaccines to Generate Potent and Long-lasting CD8+ Responses


  • Learning from preclinical models to guide and optimize mRNA-based
    vaccine platforms
  • Deciding the best combination therapy to use with mRNA
  • Determining anti-tumor T cell efficacy and future directions

4:00 pm End of Day One